When to Use Triple Therapy in AF Patients with ACS
Triple therapy (oral anticoagulant + aspirin + P2Y12 inhibitor) should be used for ≤1 week after PCI in AF patients with ACS, and only extended up to 1 month in patients at high thrombotic risk with acceptable bleeding risk. 1
Default Strategy: Early Aspirin Cessation
The current evidence strongly favors early cessation of aspirin with continuation of dual therapy (oral anticoagulant + P2Y12 inhibitor) as the standard approach. The 2024 ESC guidelines explicitly recommend early cessation (≤1 week) of aspirin in AF patients with ACS undergoing uncomplicated PCI, particularly when thrombosis risk is low or bleeding risk is high 1.
Duration Algorithm
Immediate Post-PCI Period (During Hospitalization)
- All patients: Triple therapy during inpatient stay until discharge
- Duration: Up to 1 week maximum 1, 2
Extended Triple Therapy (Up to 1 Month)
Only consider if ALL of the following apply:
- High thrombotic/ischemic risk features present
- Acceptable/low bleeding risk (HAS-BLED score consideration)
- Complex PCI features (e.g., left main stenting, bifurcation lesions, multiple stents)
- Maximum duration: 30 days 3, 2
After Triple Therapy Period
- Months 1-12: Dual therapy with oral anticoagulant + P2Y12 inhibitor (preferably clopidogrel) 1
- Beyond 12 months: Oral anticoagulant monotherapy 1
Critical Medication Choices
Oral Anticoagulant Selection
DOACs are strongly preferred over VKAs when combination antithrombotic therapy is needed 1, 3. The AUGUSTUS trial demonstrated that apixaban significantly reduced total bleeding events compared to VKA (rate ratio 0.66) without increasing ischemic events 4, 5.
P2Y12 Inhibitor Selection
Clopidogrel is preferred over potent P2Y12 inhibitors (prasugrel, ticagrelor) when used with oral anticoagulation 3, 2. Patients on high-potency P2Y12 inhibitors experienced more multiple bleeding events 4.
Aspirin Dosing
When aspirin must be used, limit to ≤100 mg daily 3.
Evidence Strength
The recommendation against routine triple therapy is supported by five major randomized trials (WOEST, PIONEER AF-PCI, RE-DUAL PCI, AUGUSTUS, ENTRUST-AF PCI) that consistently showed dual therapy reduced major bleeding by 30-50% compared to triple therapy, with non-inferior ischemic outcomes 3, 6. The AUGUSTUS trial specifically showed aspirin doubled total bleeding risk (rate ratio 2.14) without reducing ischemic events 4.
Common Pitfalls to Avoid
- Do not continue triple therapy beyond 1 month in most patients—the bleeding risk outweighs any theoretical ischemic benefit
- Do not use triple therapy routinely—it should be the exception, not the rule 3
- Do not combine VKA with dual antiplatelet therapy when a DOAC is available and appropriate 1
- Do not use potent P2Y12 inhibitors (prasugrel/ticagrelor) when combining with oral anticoagulation—stick with clopidogrel 3
High Thrombotic Risk Features
While guidelines recommend individualization, high thrombotic risk typically includes:
- Complex coronary anatomy requiring complex PCI
- Prior stent thrombosis
- Extensive coronary disease with multiple stents
- Left main or proximal LAD stenting
However, even in these cases, triple therapy should not exceed 30 days 3, 2.